IVIEW Therapeutics is pleased to announce the appointment of Jeanette Stewart, RN, as the Director of Clinical Operations Bringing more than 30 years of expertise in ophthalmic clinical research, Ms. Stewart is a seasoned professional who has successfully managed clinical trials across all stages of development. She is the CEO…
Read More
First Patient Dosed in Phase 2b Clinical Trial of IVW-1001 for Dry Eye Disease IVIEW Therapeutics today announced that the first patient has been dosed in its Phase 2b clinical trial evaluating IVW-1001, a novel topical therapy for dry eye disease. The initial dosing was conducted at the Eye Research…
Read More
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement…
Read More
IVIEW Therapeutics Presents Breakthrough GVB-2001 Gene Therapy for Glaucoma at CCRVO The 13th Congress of Chinese Research in Vision and Ophthalmology (CCRVO), jointly organized by the Chinese Medical Association and its Ophthalmology Branch, was held in Chongqing from July 24–27, 2025. As one of the two premier Category I academic…
Read More
Wellsheet launches multidisciplinary AI Copilot to reduce charting time by 50% AI improves chart summarization, multidisciplinary rounding coordination and streamlines discharge planning and documentation NEW YORK, July 17, 2025 /PRNewswire/ -- Wellsheet, a leader in AI clinical workflows and operations, today announced a new Care Team Copilot that combines chart summarization, multidisciplinary rounding and…
Read More
Summit Pharmaceuticals Signed an Exclusive Distributorship Agreement with Accelerated Biosciences, US Cell Provider Summit Pharmaceuticals International Corporation (Headquarters: Hitotsubashi, Chiyoda-ku, Tokyo, President & CEO: Katsuya Okuyama, hereinafter “SPI”) has signed an exclusive distributorship agreement with Accelerated Biosciences (Headquarters: Philadelphia, USA; CEO: Yuta Lee, hereinafter “AB”), a US-based company to expand…
Read More
ImmunoGenesis Announces the Formation of Scientific Advisory Board Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies HOUSTON, July 01,…
Read More
Kayothera Named as a Winner of the American Diabetes Association’s Innovation Challenge to Transform Type 2 Diabetes Care Seattle, WA — June 21, 2025, Kayothera, Inc., a preclinical-stage therapeutics company pioneering first-in-class, oral inhibitors of the retinoid nuclear receptor pathway, today announced that it has been recognized as one of the…
Read More
Bainbridge Health Welcomes B. Braun to the National Infusion Collaborative™ Bainbridge Health announced that B. Braun Medical Inc. (B. Braun) has joined the National Infusion Collaborative (NIC) PHILADELPHIA, PA, UNITED STATES, June 10, 2025 /EINPresswire.com/ -- Bainbridge Health, a leading provider of medication safety and stewardship solutions, today announced that…
Read More
Latus Bio Strengthens Executive Team with Appointments of Ainslie Little as COO and Katie Hewitt as interim CBO BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company driving advances in AAV gene therapy, announces the appointments of Ainslie Little, PhD, as COO and Katie Hewitt, as interim CBO. “These appointments reflect…
Read More
Vittoria Biotherapeutics to Share Trials-in-Progress Presentation from Phase 1 Study of VIPER-101 at ASCO 2025 Annual Meeting Trial is evaluating VIPER-101, a novel, gene-edited, autologous dual-population CAR-T therapy in patients with T-cell lymphoma PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics Inc., a clinical-stage immunotherapy company specializing in the development of innovative…
Read More
Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene…
Read More
Latus Bio Announces Publication of Breakthrough Research on Novel AAV Capsid Variant for Huntington’s and Parkinson’s Disease Gene Therapy PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research manuscript in Nature Communications: “Optimized AAV capsids for basal…
Read More
Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, “AAVs engineered for robust brain transduction drive therapeutically relevant expression of secreted recombinant…
Read More
Source: Cancer Focus Fund ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001 for Advanced Solid Tumors to Ochsner MD Anderson Cancer Center First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies Promising early signals of activity seen as…
Read More
Latus Bio Announces Multiple Oral and Poster Presentations at the Upcoming American Society for Gene and Cell Therapy Annual Meeting PHILADELPHIA--(BUSINESS WIRE)--Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and poster presentations at the American Society for Gene and Cell Therapy (ASGCT)…
Read More
Strados Labs Introduces Grant Initiative to Accelerate Research into Continuous Lung Sound Monitoring The new program provides eligible research studies with in-kind support for the use of the RESP® Biosensor system. by Strados Labs | Mar 25, 2025 | Press Releases Philadelphia, PA, March 20, 2025 – Strados Labs, a medical technology company, is…
Read More
ImmunoGenesis Doses First Patient in Phase 1/2 Clinical Trial of IMGS-101 in Combination With Balstilimab (anti-PD-1) and Zalifrelimab (anti-CTLA-4) in Relapsed or Refractory Advanced Prostate, Pancreatic, and HPV(-) Head & Neck Tumors IMGS-101 is the only known reducer of solid tumor hypoxia, offering the potential to enhance the efficacy of…
Read More
BioAdvance Capital Fuels Life Sciences Innovation with Nine New Investments Expands Portfolio with Cutting-Edge Innovations in Gene Therapy, AI-Driven Drug Discovery, and Precision Medicine and Reaffirms Investments in Existing Portfolio Philadelphia, PA – February 25, 2025 – In 2024, BioAdvance Capital continued its mission to foster early-stage healthcare innovation in…
Read More
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug candidate at the 20th Annual CHDI Huntington’s Disease (HD) Therapeutics…
Read More